High muc16 expression is associated with poor real-world overall survival in patients with high-grade serous ovarian carcinoma
IGCS 2026
Robert Coleman, Lauren Dockery, Kathleen Moore, R. Naumann, Michelle Rowland, Dayana Delgado, Lennart Langouche, Kathleen Keegan, David Lennon, Ashwini Pai, Dhiren Patel, David O'Malley
Introduction
Mucin 16 (MUC16), a glycoprotein involved in tumor cell proliferation, metastasis, and immune evasion, is cleaved to form serum CA125. MUC16 is overexpressed in ∼80% of epithelial ovarian cancers (OC), making MUC16 a promising therapeutic target. We assessed the potential prognostic association between MUC16 expression and real-world overall survival (rwOS) in patients with high-grade serous ovarian carcinoma (HGSOC).
Methods
Tumor MUC16 expression (log2[TPM]+1) and serum/plasma CA125 from patients with HGSOC in a de-identified real-world database (Tempus AI, Inc.) were stratified by median MUC16 expression (low versus high), and their association with rwOS was evaluated using a multivariate Cox proportional hazards model adjusted for prognostic variables.
Results
Across 254 patients, median rwOS was significantly shorter with high (≥9.24) versus low (<9.24) MUC16 expression (log-rank P=0.0144; Figure 1). Multivariate analysis showed high MUC16 expression (HR 2.34; P=0.0014), BRCA status (HR 0.24; P=0.007), and HRD status (HR 0.43; P=0.01) were independently associated with rwOS. Median rwOS was shorter with high versus low (>70 vs ≤70 U/mL) CA125 in patients starting 1L (n=302; log-rank P=0.0104) or 2L+ (n=223; log-rank P=0.00038; Figure 2) treatment. Multivariate analysis confirmed high CA125 was associated with worse median rwOS in 1L (HR 2.15; P=0.0284) and 2L+ (HR 1.83; P=0.00227) cohorts.
Conclusion/Implications
High MUC16 expression is associated with poor rwOS in HGSOC, independent of BRCA/HRD status, identifying a population with high unmet need. HWK-016, a novel ADC targeting the non-shed MUC16 extracellular domain, is being evaluated in a phase 1 trial in patients with solid tumors, including OC (NCT07470853).
Related publications